Pfizer secures FDA approval for Velsipity to treat active ulcerative colitis in adults
Velsipity is an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, approved by the US FDA to treat moderately…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Oct 23
Velsipity is an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator, approved by the US FDA to treat moderately…
16 Oct 23
Skyrizi is an interleukin-23 inhibitor that selectively blocks IL-23, a cytokine involved in inflammatory processes and is associated…
16 Oct 23
The designation was given based on positive data from the Phase 1 part of the ongoing Phase 1/2…
16 Oct 23
NewChem Technologies is a contract services provider and supplies customers in pharmaceuticals, diagnostics and biotechnology to veterinary science…
16 Oct 23
With no dose-limiting toxicities observed, treatment of second dose cohort to begin
16 Oct 23
The Company will host an investor event following the presentation after the close of market on Thursday, November 2nd
16 Oct 23
Fezolinetant is an investigational nonhormonal treatment for vasomotor symptoms (VMS) associated with menopause
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
13 Oct 23
Braftovi plus Mektovi is indicated for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) with…
13 Oct 23
By adding the new expanded production line, AGC Biologics can now provide more plasmid material in high-quality and…
13 Oct 23
In the mirikizumab arm of the study, 45.4% of patients achieved clinical response at week 12 and clinical…